Molbio Diagnostics Q2 FY27 Financial Results and Executive Departure
Molbio Diagnostics Ltd · Financial Result · 06 Nov 2026, 12:56 am
Molbio Diagnostics Q2 FY27 Financial Results and Executive Departure Molbio Diagnostics reported Q2 FY27 consolidated revenue from operations of ₹2,590.20 Mn, down 55.4% YoY from ₹5,802.67 Mn in Q2 FY26 and 36.6% QoQ from ₹4,083.76 Mn. Consolidated net profit dropped 92.8% YoY to ₹77.01 Mn versus ₹1,068.43 Mn, with diluted EPS sliding to ₹1.33. H1 FY27 consolidated net cash from operations stood at ₹1,671.21 Mn. Separately, Dr. Kuldeep Singh Sachdeva resigned as President & CMO (effective 21st Jan'27), and Rakesh Hulihalli & Associates was appointed Secretarial Auditor for five years.
Original exchange filing (PDF)
More announcements from Molbio Diagnostics Ltd
- Transcript of Earnings Call with analysts and investors for the quarter and half year ended on September 30, 2026 · 11 Nov 2026
- Monitoring Agency Report on the utilization of proceeds raised through issuance of equity shares by way of Public Issue of the Company · 07 Nov 2026
- Audio Recording of Earnings call held on November 05,2026 for the quarter and half year ended September 30,2026. · 06 Nov 2026
- Investor presentation · 05 Nov 2026
- Outcome of the Board Meeting · 05 Nov 2026
- Molbio Diagnostics Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 05 Nov 2026
- Intimation of Earnings Conference Call on November 05, 2026, at 05:30 P.M. IST to discuss the financial performance of the Company for the quarter and half year ended September 30, 2026. · 05 Nov 2026
- To consider and approve the Unaudited financial results (Standalone & Consolidated) for the quarter and half year ended September 30, 2026 · 05 Nov 2026
